DOI 10.1080/14796694.2026.2661772
Real-world clinical outcomes in patients with biochemical recurrence after local therapy for non-metastatic prostate cancer.
Аннотация
AIMS: We assessed the proportion of patients with biochemical recurrence (BCR), the occurrence of BCR in risk groups according to prostate-specific antigen doubling time (PSA-DT), and clinical outcomes in risk groups.
PATIENTS AND
METHODS
Retrospective observational study of patients with non-metastatic prostate cancer (PC) (n = 26,755) in the US using the Optum® PC electronic medical record database. Primary outcomes were the proportion of patients with BCR in prior radical prostatectomy (RP) or radiation therapy (RT) cohorts. Secondary outcomes included association between baseline characteristics and time to BCR, BCR risk group (high-risk: PSA-DT <12 months; low-risk: PSA-DT ≥12 months), and time from BCR to metastasis and castration-resistant PC (CRPC).
RESULTS
BCR occurred in 19.7% of patients after RP and 8.8% after RT. Among high-risk BCR patients (n = 523) in the RP cohort, 19.3% developed metastasis, 14.5% developed CRPC, and 14.1% died. In contrast, among low-risk BCR patients (n = 1,356), rates were 10.2%, 7.0%, and 6.6%, respectively. In the RT cohort, 25.9% of the high-risk BCR patients (n = 498) developed metastasis, 21.5% developed CRPC, and 19.7% died, compared with 16.4%, 9.0%, and 16.4% among low-risk patients (n = 122), respectively.
CONCLUSIONS
PSA and PSA-DT are key predictors of BCR. Outcomes are worse among high-risk BCR patients with short PSA-DT.
Предметные рубрики MeSH
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.